The Lambert Initiative for Cannabinoid Therapeutics
Advancing cannabinoid-based treatments to alleviate human suffering
The Lambert initiative is an Australian first in the field of medicinal cannabinoids.
It will explore the potential of compounds derived from the cannabis plant (cannabinoids) in treating a range of diseases. Our approach will involve medicinal chemistry, cellular and preclinical research, early human testing and clinical trials in patients.
The Lambert Initiative will also translate research outcomes into practice by providing training to health professionals and engaging consumer organisations and media to educate the public and transform current policy.
Our overall aim is to optimise and introduce safe and effective cannabinoid therapeutics into mainstream medicine in Australia and beyond.
We will target a range of conditions including paediatric epilepsy, cancer, chronic pain, obesity, dementia and mental health disorders.
A pioneering study launches today not only to identify issues facing families living with epilepsy but also to analyse cannabis products being used in the community.
A promising major advance for cannabis-based medications.
Three-year-old Katelyn Lambert has Dravet Syndrome, a rare and extreme form of epilepsy. Without any new treatments Katelyn faces a lifetime of seizures and moderate to severe mental retardation.